key: cord-1046199-rchgkjli
authors: Zazzara, Maria Beatrice; Bellieni, Andrea; Calvani, Riccardo; Coelho-Junior, Hélio Jose; Picca, Anna; Marzetti, Emanuele
title: Inflamm-aging at the time of COVID-19
date: 2022-03-21
journal: Clin Geriatr Med
DOI: 10.1016/j.cger.2022.03.003
sha: 72411487e99c3db0fa93153cea27312c7a4d97fb
doc_id: 1046199
cord_uid: rchgkjli

Severe COVID-19 is associated with overproduction of pro-inflammatory cytokines. The ensuing cytokine storm contributes to the development of severe pneumonia and, possibly, to long-term symptom persistence (long COVID). The chronic state of low-grade inflammation that accompanies aging (inflamm-aging) might predispose older adults to severe COVID-19. Inflamm-aging may also contribute to symptom persistence following acute COVID-19. Anti-inflammatory drugs and immunomodulatory agents can achieve significant therapeutic gain during acute COVID-19. Lifestyle interventions (e.g., physical activity, diet) may be proposed as strategies to counteract inflammation and mitigate long-term symptom persistence.

With more than 400 million confirmed cases and nearly 6 million deaths, 1 the Coronavirus disease 2019 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly affected everyone's life. The majority of people infected with SARS-CoV-2 have a self-limiting infection and do recover; others suffer a more severe disease, with 10% of cases requiring intensive care unit (ICU) admission. 2 The case fatality rate of COVID-19 is approximately 1.5% (https://covid19.who.int/). Most COVID-19-related deaths occurred in those 60 years and older and an even higher mortality was registered amongst the oldest old (i.e., ≥80 years). 3 The presence of a least one underlying chronic condition (e.g., cancer, diabetes, hypertension, obesity, cardiovascular disease, cerebrovascular disease) is a major risk factor for death. [4] [5] [6] Older adults are more susceptible to SARS-CoV-2 infection, more prone to develop severe COVID-19, and more frequently admitted to ICUs, with consequent increased mortality. 3, 5 An extraordinary proliferation of studies suggests that SARS-CoV-2 infection unleashes an abnormal inflammatory response, the so-called cytokine storm. Indeed, severe COVID-19 in hospitalized patients is characterized by high circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-), and lymphopenia. 7 The abnormal inflammatory response, along with hypercoagulability and defective viral clearance, contributes to the development of severe pneumonia and acute respiratory distress syndrome (ARDS), with subsequent end-organ damage, multiorgan system failure, and eventually death. 8 While severe COVID-19 disproportionally affects older people, systemic inflammation during SARS-CoV-2 infection is detected in patients of all ages, including children, in whom a severe multisystem inflammatory syndrome with features of Kawasaki has been described. 9 . This implies that COVID-19-induced inflammation is not per se sufficient at inducing negative health outcomes. In the next sections, we provide a pathophysiologic view of COVID-19 in older adults within the frame of inflamm-aging with a focus on anti-inflammatory treatments for acute and post-acute disease.

J o u r n a l P r e -p r o o f

Aging is a complex phenomenon characterized by numerous changes that result from environmental, stochastic, genetic, and epigenetic events in different cell types and tissues. 10 One of the most accredited hypotheses on the "pathogenesis" of aging stems from the observation that older organisms tend to develop a pro-inflammatory status sustained by elevated circulating levels of inflammatory biomolecules. 10, 11 Inflammation is instrumental to combat infections or other exogen pathogens; however, when it becomes sustained and prolonged it can be detrimental to health. The state of chronic, sterile, inflammatory process that accompanies aging is termed as inflamm-aging 11 and is associated with a decline in the efficiency of the immune system, named immunosenescence. 12 Hence, immunosenescence and inflamm-aging are two separate but highly intertwined entities that concur to progressively reduce the immune system ability to trigger an effective antibody and cellular response to infections and vaccinations, and are associated with increased incidence of cancer and autoimmune diseases. 13 Immunosenescence and inflamm-aging can be accelerated by different factors, such as persistent tissue damage, environmental stressors, unhealthy lifestyles, and social and psychological stress, and could explain differences in resistance to SARS-CoV-2 infection between younger and older adults, and genders. 14 In this complicated picture, centenarians are "outliers" characterized by high circulating levels of anti-inflammatory biomarkers that protect them against common age-related conditions and possibly from severe COVID-19. 14 Inflamm-aging plays a pivotal role in most geriatric conditions, such as sarcopenia, frailty, and disability, and is a major risk factor for several age-associated chronic diseases (e.g., cardiovascular disease, metabolic syndrome, diabetes, cancer, autoimmune disorders, dementia multimorbidity), 11, 15, 16 all of which are linked to increased COVID-19 fatality. 4 The mechanisms underlying this chronic inflammatory response are difficult to decipher and are still under intense investigation. The accumulation of senescent cells is one of the mechanisms implicated in the pathogenesis of chronic inflammation. 17 Several factors contribute to cellular J o u r n a l P r e -p r o o f senescence, including, among others, oxidative stress, genomic instability, metabolic derangement, and altered proteostasis. 10 Senescence is characterized by the arrest of cell proliferation and secretion of senescence-associated secretory phenotype (SASP) factors including pro-inflammatory cytokines and chemokines. 11 In addition, damaged cellular and organellar components are recognized by a network of sensors and trigger further secretion of inflammatory biomolecule. 18 Other sources of inflamm-aging are harmful products of commensal microbes, such as oral and gut microbiota. 19 During aging, the composition of gut microbiota changes with reduced diversity and enrichment in pro-inflammatory bacteria. 20 This age-related gut "dysbiosis" may alter the morphology and barrier properties of the intestinal mucosa with increased permeability ("leaky gut"). 20 Age-related changes in both the innated and adaptive immune system play an important role in the pathophysiology of inflamm-aging. Declines in the number, function, and activation of cells involved in the immune response, along with the depletion of hematopoietic stem cells and alteration in the coagulation system, are major phenotypes of immunosenescence. 12 Adaptive immunity declines with age, whereas innate immunity undergoes more subtle changes that could result in mild hyperactivity. 12 Defective regulation of the complement pathways and increased activation of the coagulation system can also determine local inflammatory reactions and lead to the development of degenerative diseases. 12 Chronic inflammation involves several cytokines, molecular pathways, effector cells, and tissue responses that appear to be shared across age-related diseases. Clinically, it is characterized by moderately elevated serum levels of several inflammatory biomarkers, including CRP, IL-6, IL-18, and TNF-α. 11,21 IL-6 is considered to be the most prominent cytokine that is shared across agerelated disease conditions. 21 IL-6 serum levels also predict incident disability and frailty, 22 with a risk of developing mobility disability increasing linearly for concentrations higher than 2.5 pg/mL. 23 As such, IL-6 is hallmark of chronic morbidity and a commonly used biomarker of inflammaging. 21 J o u r n a l P r e -p r o o f

Bacterial or viral infections and/or vaccinations usually an immune response that confers an immunological memory. The history of the individual exposure to different antigens shapes our "immunobiography" and influences the degree and characteristics of the inflammatory response to a new stimulus. 24 This trained immunity often results in a more active and functional immune system. 24 Immunosenenesce and inflamm-aging negatively impact the immune response to pathogens, including SARS-CoV-2, which explains, at least partly, the development of more severe clinical manifestations in older adults. 25, 26 In the early phases of COVID-19, infected cells release damage-associated molecular patterns (DAMPs), such as ATP and nucleic acids, which are recognized by lung epithelial and endothelial cells, and alveolar macrophages. This process triggers the production of various pro-inflammatory cytokines and chemokines allowing recruitment of innate and acquired immune cells to the site of infection. 27 The activation of virus-specific CD4+ and CD8+ T cells kills infected cells. However, in the case of a dysfunctional immune response, the accumulation of immune cells in the lungs leads to the overproduction of pro-inflammatory cytokines, especially IL-6, causing damage to local cells and tissue, and with subsequent systemic implications. 28 In older adults, a more robust age-dependent activation on innate pro-inflammatory pathways is believed to increase the risk of severe disease. 23, 26, 28 In older men, IL-6 is chronically upregulated, with a higher rate of inflamm-aging which might explain the greater risk of death by COVID-19 compared with women. 28, 29 Pathophysiological pathways in COVID-19 and risk factors for negative outcomes in individuals affected by SARS-CoV-2 share several underlying mechanisms that regulate inflammation, which might impact the clinical course of COVID-19, from flu-like syndrome to severe respiratory failure and death. 30 Moreover, an acute COVID-19 episode may induce accumulation of subclinical damages that predisposes to a chronic pro-inflammatory state, even when the episode is mild and clinically resolved with no apparent immediate consequences. 30 Indeed, a substantial share of COVID-19 survivors experience symptoms J o u r n a l P r e -p r o o f persistence for weeks or months after viral clearance. 31 This condition, known as post-COVID or "long COVID", is an increasingly recognized public health issue. 32 Common long-lasting signs and symptoms include cough, fever, dyspnea, fatigue, musculoskeletal (myalgia, joint pain) and gastrointestinal complaints, and anosmia/dysgeusia. 33 In the post-acute phase, some patients show an accelerated decline in physical, cognitive, and functional abilities that resemble age-related long-term impairments. 31 Evidence shows that cytokine levels are still elevated in patients with long COVID and the maintenance of a low-grade chronic inflammation could be one of the mechanisms that could explain the etiology of symptom persistence. 30, 34, 35 From this perspective, long COVID bears resemblance with post-intensive care syndrome (PICS). Patients with PICS present cognitive, psychological and physical disabilities, and some never fully recover. 36 Physical impairment in PICS often involves muscle weakness and fatigability, and symptoms of deconditioning, 36 all cardinal features of age-related frailty and sarcopenia. 15, 37 Finally, it is worth mentioning that the long-term effects of COVID-19 on health, functional status and quality of life may be further worsened by social distancing, isolation, and financial difficulties. 38 This indicates that the management of long COVID requires comprehensive approaches similar to those developed based on comprehensive geriatric assessment. 39 

Since the beginning of the pandemic, studies on COVID-19 treatments have mostly focused on quenching the uncontrolled inflammatory response. The RECOVERY trial has been a cornerstone in the field by showing that dexamethasone significantly reduces mortality in patients with severe COVID-19 required supplemental oxygen. 40 Dexamethasone is a synthetic glucocorticoid with broad immunosuppressive properties, which downregulates the differentiation of B and T cells and inhibits the production of pro-inflammatory cytokines and chemokines. 41 Other agents targeting specifically IL-1 and IL-6 have become routinely used in the management of critical ill COVID-19 patients. Tocilizumab and sarilumab are IL-6 receptor blockers that have J o u r n a l P r e -p r o o f proven to be lifesaving in patients with COVID-19 who are severely or critically ill and are now recommended by the World Health Organization (WHO), especially when administered alongside with corticosteroids. [42] [43] [44] More recently, the European Medical Agency (EMA) approved the use of anakirna, a recombinant IL-1 receptor antagonist (IL-1Ra), in COVID-19 patients with increased risk of disease progression to respiratory failure identified by early increase in soluble urokinase plasminogen activator receptor (suPAR) serum levels. 45, 46 However, the use of immunosuppressants in older adults is associated with several adverse effects and can expose frailer individuals to increased risk of secondary bacterial and fungal infection during hospitalization. [47] [48] [49] In patients with long COVID, lifestyle interventions can effectively counteract chronic inflammation independent of underlying chronic conditions, and may therefore be proposed as strategies to mitigate long-term symptom persistence. 50 Physical activity and specific nutritional strategies may be especially suitable for older adults for their potential of reducing inflamm-aging and supporting successful immune aging. 50, 51 Indeed, regular physical activity has been associated with enhanced innate and adaptive immune functions, thereby attenuating mechanisms linked to immunesenescence. 51, 52 Studies have shown that physical activity improves natural killer and neutrophil function, as well as T-cell proliferation. 51, 53 Furthermore, aerobic physical exercise may induce cell death in apoptosis-resistance senescent T-lymphocytes and increase the pool of naïve Tcells. 53 Notably, physical activity reduces the expression of toll-like receptors, transmembrane glycoproteins that initiate an immune response following recognition of DAMPs or other endogenous agents, with consequent reduced secretion of pro-inflammatory cytokines. 51 Furthermore, physical activity promotes the secretion of controlled levels of IL-6 that stimulates the production of immune-regulatory mediators such as IL-1ra, IL-8, IL-10, thereby regulating the balance between pro-inflammatory and anti-inflammatory factors and contributing the immune homeostasis. 54, 55 Similar to physical activity, dietary habits play an important role in shaping the immune system and appropriate nutritional interventions have shown to attenuate inflammation. 51, 56 Pro-inflammatory diets characterized by insufficient consumption of fruits, vegetables and whole J o u r n a l P r e -p r o o f grains, and excessive use of saturated fats, meat, processed foods, and refined sugars can induce a chronic elevation in inflammatory cytokines even in younger adults. 57 Conversely, healthy eating patterns, such as the Mediterranean diet and vegetarian diets, may ameliorate the inflammatory process and oxidative stress, maintain gut microbial eubiosis, and decrease circulating levels inflammatory biomarkers. 56, 58, 59 The NU-AGE ("New dietary strategies addressing the specific needs of the elderly population for healthy aging in Europe") project has demonstrated the feasibility of a tailored Mediterranean-like dietary pattern, specifically designed to meet dietary needs of older adults aged 65 years old and older as a comprehensive dietary strategy to reduce inflamm-aging and improve health and quality of life older adults. 60 Whether such an approach may help reduce the burden of symptom persistence in older COVID-19 survivors warrants exploration.

Inflamm-aging and SARS-CoV-2 infection interact in an interplay that involves both acute inflammation and low-grade chronic inflammation, predisposing older adults to severe COVID-19.

During the acute phase, the precipitating factor is represented by an aberrant immune response characterized by the overproduction of pro-inflammatory cytokines. Elevated cytokine levels may persist long after viral clearance and are potentially responsible of the installment of low-grade chronic inflammation and the persistence of long-lasting COVID-19 symptoms. Therapeutic approaches targeting inflammation have proven to be effective in reducing mortality during an acute COVID-19 episode. However, at the time of writing, no standard treatment is available for the post-acute phase. Albeit further research is needed, lifestyle interventions − physical activity and specific nutritional strategies − can effectively counteract chronic inflammation and may therefore be proposed as strategies to mitigate long-term symptom persistence.

• Inflamm-aging along with the abnormal inflammatory response to SARS-CoV-2 predisposes older adults to severe COVID-19.

• Targeting inflammation is key during the acute phase and reduces COVID-19 lethality.

• Behavioral interventions such as physical activity and optimal diet should recommended to counteract symptom persistence following acute COVID-19.

World Health Organization. WHO coronavirus (COVID-19) dashboard

Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Clinical characteristics of Coronavirus disease 2019 in China

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Cytokine storm

COVID-19 cytokine storm: the interplay between inflammation and coagulation

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study

The hallmarks of aging

Inflamm-aging: an evolutionary perspective on immunosenescence

Age and immunity: What is "immunosenescence

Aging and the immune system: The impact of immunosenescence infection, immunity and vaccine immunogenicity

SARS-CoV-2, immunosenescence and inflammaging: Partners in the COVID-19 crime

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

Inflammaging: a new immunemetabolic viewpoint for age-related diseases

Cellular senescence: When bad things happen to good cells

Cell death and inflammation: The role of mitochondria in health and disease

The aging gut microbiota: New perspectives

Gut microbiota as the key controllers of "healthy" aging of elderly people

Interleukin-6 in aging and chronic disease: A magnificent pathway

Inflammation and frailty in the elderly: A systematic review and meta-analysis

Serum IL-6 level and the development of disability in older persons

Immunobiography and the heterogeneity of immune responses in the elderly: A focus on inflammaging and trained immunity

The epigenetic landscape of age-related diseases: the geroscience perspective

How immunosenescence and inflammaging may contribute to hyperinflammatory syndrome in COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

Interleukin-6 and severe COVID-19: A systematic review and meta-analysis

A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity

A public health perspective of aging: Do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short-and long-term inflammaging?

Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea

World Health Organization. Coronavirus disease (COVID-19): Post COVID-19 condition

Persistent symptoms in patients after acute COVID-19

Post-COVID syndrome: An insight on its pathogenesis

Long covid -Mechanisms, risk factors, and management

Post-intensive care syndrome: An overview

Frailty and sarcopenia: The potential role of an aged immune system

The mental health consequences of COVID-19 and physical distancing: The need for prevention and early intervention

Gemelli Against COVID-19 Post-Acute Care Study Group. Post-COVID-19 global health strategies: The need for an interdisciplinary approach

Dexamethasone in hospitalized patients with Covid-19

After 62 years of regulating immunity, dexamethasone meets COVID-19

A living WHO guideline on drugs for covid-19

Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19

Therapeutics and COVID-19: living guidelines. Available at

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Anakinra for severe forms of COVID-19: A cohort study

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: A prospective observational study

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

The COVID-19 pandemic and physical activity

Physical activity and diet shape the immune system during aging

Exercise and the aging immune system

Lifestyle exercise attenuates immunosenescence; flow cytometry analysis

The pro-and anti-inflammatory properties of the cytokine interleukin-6

Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans

Combating inflammaging through a Mediterranean whole diet approach: The NU-AGE project's conceptual framework and design

Proinflammatory diet increases circulating inflammatory biomarkers and falls risk in community-dwelling older men

The association of antiinflammatory diet ingredients and lifestyle exercise with inflammaging

Association of vegetarian diet with inflammatory biomarkers: A systematic review and meta-analysis of observational studies

Changes in dietary Intake and Adherence to the NU-AGE diet following a one-year dietary intervention among European older adults-Results of the NU-AGE randomized trial